Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Stage T1ÀÇ Ç¥À缺 ¹æ±¤Á¾¾ç¿¡¼­ BCG¿Í Mitomycin CÀÇ ¿¹¹æÈ¿°ú Prophylactic Effect of Mitomycin C and Bacillus Calmette-Guerin in Stage T1 of the Superficial Bladder Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1997³â 38±Ç 9È£ p.957 ~ 962
¼Õ±â¿î, ±èÇö¼ö, ¿ÀÅÂÈñ,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Õ±â¿î (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ¸¶»ê»ï¼ºº´¿ø

±èÇö¼ö (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ¸¶»ê»ï¼ºº´¿ø
¿ÀÅÂÈñ (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ¸¶»ê»ï¼ºº´¿ø

Abstract

°á·Ð
Stage T1ÀÇ Ç¥À缺 ¹æ±¤Á¾¾ç¿¡¼­ °æ¿äµµÀû ÀýÁ¦¼úÀ» ½ÃÇàÇÑ ÈÄ Àç¹ß¹æÁöÀÇ ¸ñÀûÀ¸·Î ½Ã
ÇàÇÑ BCG¿Í mitomycin CÀÇ ¹æ±¤³» ¾à¹°ÁÖÀÔÀÇ È¿°ú¸¦ ¾Ë±â À§ÇÏ¿© ³»½Ã°æÀû ÀýÄ¡¼ú ÈÄ
¹æ±¤³» ÁÖÀÔ¿ä¹ýÀ» ½Ç½ÃÇÏÁö ¾ÊÀº ±ºÀ» ´ëÁ¶±ºÀ¸·Î ÇÏ¿© BCG¿Í mitomycin CÀ» ÁÖÀÔÇÑ ±º
À» ºñ±³ÇÑ °á°ú BCGÁÖÀÔ±ºÀÌ mitomycin C±º°ú ´ëÁ¶±º¿¡ ºñÇÏ¿© Æò±Õ Àç¹ß±â°£Àº Åë°èÇÐ
ÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸³ª Àç¹ßÀ²Àº À¯ÀÇÇÑ Â÷ÀÌ°¡ ÀÖ°Ô ÀÛ¾Ò´Ù. ±×·¯³ª mitomycin C
±ºÀº Àç¹ßÀ² ¹× Æò±Õ Àç¹ß±â°£ ¸ðµÎ ´ëÁ¶±º°ú À¯»çÇÏ¿´´Ù. ¹æ±¤³» ÁÖÀÔÈÄÀÇ ºÎÀÛ¿ëÀº
mitomycin C±ºº¸´Ù BCG±º¿¡¼­ ´õ ¸¹ÀÌ ³ªÅ¸³µÀ¸¸ç, mitomycin C±º¿¡¼­´Â ¹æ±¤¿°ÀÌ °¡Àå
¸¹¾ÒÀ¸³ª BCG±º¿¡¼­´Â Ç÷´¢°¡ °¡Àå ¸¹ÀÌ ³ªÅ¸³µ´Ù.
ÀÌ»óÀÇ °á°ú·Î ¹æ±¤³» ÁÖÀÔ¿ä¹ý¿¡¼­ÀÇ BCG´Â stage T1ÀÇ Ç¥À缺 ¹æ±¤Á¾¾çȯÀÚ¿¡¼­ °æ¿ä
µµÀû ÀýÁ¦¼ú ÈÄ Àç¹ßÀ» ¿¹¹æÇϴµ¥ È¿°úÀûÀÎ ¾à¹°·Î »ý°¢µÇ¸ç mitomycin C´Â ºÎÀÛ¿ëÀº Àû
À¸³ª ±× È¿°ú°¡ ´ëÁ¶±º°ú À¯»çÇÏ¿© ´õ ¸¹Àº Áõ·Ê¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
We compared the efficacy and toxicity of mitomycin C and Bacillus Calmette-Guerin
(BCG) intravesical instillation in 86 patients with stage T1 of the superficial bladder
tumor. Of them, 34 patients were received mitomycin C (40 §·/40 §¢ sodium chloride,
once a week for 8 weeks) and 26 patients were received BCG (120 §·/50 §¢ sodium
chlorids, once a week for 6 weeks) after transurethrat resection of bladder tumor and 24
patients (control) underwent transurethral resection alone. The mean follow up period
was 24.8 months in control group, 26.8 months in mitomycin C group and 25.7 months
in BCG group. The mean time to recur was 11.3 months in control group, 11.5 months
in mitomcyin C group and 15.9 in BCG group but there was no significant difference
among each groups (p>0.05). The overall recurrence rate was 34.6% in BCG group
compared with 70.5% in mitomycin C group and 75.0% in control group, showing
significant difference (p<0.05).
Side effects were more common after BCG instillation than mitomycin C instillation.
The most common side effect after BCG instillation was hematuria in 14 patients
(53.8%). That of mitomycin C was cystitis in 10 patients (29.4%).
Our study suggests that the prophylactic efficacy of BCG was significantly superior to
that of mitomycin C, but there was no significant superiority regarding prophylactic
effect of reduced mean time to recur in stage T1 bladder cancer patients. Additionally,
further follow up studies were needed in mitomycln C.

Å°¿öµå

Intravesical instillation; Mitomycin C; BCG; Superficial bladder tumor;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS